Compare · Head-to-head
MK-677 vs Tesamorelin.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Tesamorelin, then use the table to confirm fit.
Tesamorelin is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | MK-677 | Tesamorelin |
|---|---|---|
| Primary fit | muscle growth & strength and longevity & anti-aging comparisons | fat loss & metabolism and gh axis optimization comparisons |
| Evidence | Tier C | Tier A |
| Risk | med-high | low |
| Experience level | advanced | advanced |
| Budget tier | mid | premium |
| Administration route | oral | subcutaneous |
02 · Use case & timing
| Decision factor | MK-677 | Tesamorelin |
|---|---|---|
| Goal fit | Muscle Growth & Strength, Longevity & Anti-Aging, GH Axis Optimization | Fat Loss & Metabolism, GH Axis Optimization |
| What users compare it for | Increased GH/IGF-1 signaling, appetite rise, and potential lean-mass increase in some human studies. | Visceral fat reduction in HIV lipodystrophy (evidence-backed). General weight loss claims are limited. |
| Onset timeline | GH rises acutely; IGF-1 and body-composition effects are tracked over weeks to months. | Clinical endpoints assessed at 26 weeks in pivotal studies. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | MK-677 | Tesamorelin |
|---|---|---|
| Adverse effects | Edema, increased appetite, insulin resistance, elevated fasting glucose, joint discomfort, and possible cardiovascular safety concerns. | Increased neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance/diabetes, hypersensitivity. |
| Contraindications | Use caution in diabetes, insulin resistance, edema-prone states, heart failure risk, and active malignancy. | Active malignancy, pregnancy, pituitary gland disorders (per label). |
| Interaction notes | Combining with other GH-axis compounds increases endocrine complexity and may worsen glucose control. | CYP450-metabolized drugs; glucocorticoid replacement requirements may be affected. |
| Regulatory status | Not approved | Prescription-approved |
| FDA flag | FDA compounding caution | No current flag noted |
| WADA status | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | MK-677 | Tesamorelin |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54 | No age guidance yet |
| Life-stage note | Most often discussed for younger and midlife adults, but metabolic and fluid-retention risks narrow the fit quickly with age. | Not yet documented |
| Monitoring burden | high | Not specified |
| Follow-up cadence | More frequent early follow-up, then reassessment every few months if continued. | Not yet documented |
05 · Cost & sourcing
| Decision factor | MK-677 | Tesamorelin |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | $600.00 |
| Estimated monthly cost | No reliable estimate yet | $600.00 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | MK-677 | Tesamorelin |
|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. |
| Stack-friendly? | Usually stack-friendly | Better as a standalone decision |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.